Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — E&P Healthcare Conference 2023
14 slides from Pyc Therapeutics's conference presentation, Sep 12, 2023
Slide 1: E&P Healthcare Conference Presentation
12 September 2023 E&P HEALTHCARE CONFERENCE PRESENTATION PERTH, Australia and SAN FRANCISCO, California – 12 September 2023 PYC Therapeutics Limited (ASX:PYC) is pleased to provide a copy of the presentation that will be given by PYC’s CEO, Dr Rohan Hockings, at the E&P Healthcare Conference, 12 Sep
Slide 2: For personal use only
This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction. This ASX announcement was approved and authorised for
Slide 3: Life-changing science
For personal use only Life-changing science E&P healthcare conference September 2023
Slide 4: Disclaimer
Disclaimer The purpose of this presentation is to provide an update of the business which are outside PYC’s control. Important factors that could cause For personal use only of PYC Therapeutics Limited (ASX:PYC) [‘PYC’]. These slides have been actual results to differ materially from assumptions or
Slide 5: Executive Summary – PYC Therapeutics
Executive Summary – PYC Therapeutics For personal use only A clinical-stage drug discovery & With multiple major near-term catalysts development company including human data generation every 12 months¹ Creating first-in-class RNA drugs for Developing the class of drug with the highest patients with
Slide 6: Key points for today
For personal use only 3 key points for today: 1) Multiple assets 2) Immediate milestones 3) Higher probability of success PYC THERAPEUTICS 4
Slide 7: PYC's approach to drug development
PYC’s approach to drug development differentiated by its drug delivery platform and the potency advantage this creates For personal use only The fundamental challenge for RNA drugs is adequate delivery to the target cell PYC combines existing RNA drug design PYC’s drug delivery platform is used to a
Slide 8: PYC is progressing a pipeline of first-in-class drugs
PYC is progressing a pipeline of first-in-class drugs with disease- modifying potential into multi-billion dollar markets Historical progress Progress expected within 12 months For personal use only DISCOVERY PRE-CLINICAL IND ENABLING CLINICAL TRIALS MARKETED MARKET SIZE^ Retinitis Pigmentosa Type 1
Slide 9: Critical features differentiate PYC's path to revenue
3 critical features differentiate PYC’s path to revenue For personal use only DISCOVERY PRE-CLINICAL IND ENABLING CLINICAL TRIALS MARKETED Highest % success in The critical Retinitis Pigmentosa Type 11 2 humans input assumption The highest probability in valuation models Autosomal Dominant Optic Atr
Slide 10: Are drugs for monogenic diseases really 5-8x more likely to succeed?
Are drugs for monogenic diseases really 5-8x more likely to succeed in the clinic? For personal use only How likely is a drug targeting a monogenic disease to succeed in the clinic? Source 6x more likely than the industry average (of ~10%) with a 64% likelihood of Alnylam – pipeline successful marke
Slide 11: Non-clinical models provide early insight into clinical outcomes
Non-clinical models provide early insight into clinical outcomes – particularly in monogenic diseases “We need to understand as early as possible whether a drug candidate is safe and works in patients, not wait to find out in For personal use only clinical trials which can be expensive and time-cons
Slide 12: PYC expects human data read-outs within the next months
PYC expects 5 human data read-outs within the next 36 months WITHIN 12 MONTHS WITHIN 24 MONTHS WITHIN 36 MONTHS For personal use only Formal safety read-out Efficacy read-outs Pivotal/Registrational trial Retinitis Pigmentosa Type 11 (Phase 1) + Efficacy insights (Phase 2) (Phase 3) IND filed Formal
Slide 13: PYC's Board, Executive and Advisory teams
PYC’s Board, Executive and Advisory teams For personal use only Alan Tribe Dr Rohan Hockings Sri Mudumba Andrew Taylor Paula Cunningham Chairman Chief Executive Officer Chief Research & Development Officer Chief Financial Officer Senior VP Preclinical R&D Experience commercialising Dual-trained in m
Slide 14: A clinical-stage biotechnology company
For personal use only A clinical-stage biotechnology company Dedicated to changing the lives of patients with genetic diseases Generating critical human data read-outs every year from now on For first-in-class drug candidates with disease-modifying potential and the highest prospect of success in th